SCHEMBL25849856

SCHEMBL25849856

Cc1ccc2[nH]c(=O)c(S(=O)(=O)c3ccccc3)c(-c3ccccc3)c2c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.61
ALDH1A1 P00352 7/20 0.61
HPGD P15428 6/20 0.61
HSD17B10 Q99714 4/20 0.56
PTGS2 P35354 2/20 0.56
NPSR1 Q6W5P4 1/20 0.56
PIM1 P11309 1/20 0.56
PADI4 Q9UM07 3/20 0.54
GAA P10253 4/20 0.54
MEN1 O00255 4/20 0.54
KMT2A Q03164 4/20 0.54
MAPT P10636 3/20 0.54
HTT P42858 1/20 0.53
GFER P55789 1/20 0.53
CYP2C19 P33261 2/20 0.53
CYP1A2 P05177 1/20 0.53
CYP3A4 P08684 1/20 0.53
SMN1; SMN2 Q16637 2/20 0.52
NPC1 O15118 1/20 0.49
LMNA P02545 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17457401 0.85 CSF1R (0.62) KDM4EALDH1A1HPGDHSD17B10PTGS2
SCHEMBL22910882 0.79 KDM4E (0.65) KDM4EALDH1A1HPGDHSD17B10PTGS2
SCHEMBL25849885 0.78 KDM4E (0.64) KDM4EALDH1A1HPGDHSD17B10PTGS2
SCHEMBL25849861 0.77 PIM1 (0.66) KDM4EALDH1A1HPGDHSD17B10PTGS2
SCHEMBL16111911 0.77 KDM4E (0.64) KDM4EALDH1A1HPGDHSD17B10PTGS2
SCHEMBL25849874 0.75 KDM4E (0.60) KDM4EALDH1A1HPGDHSD17B10PTGS2
SCHEMBL25849868 0.75 KDM4E (0.74) KDM4EALDH1A1HPGDHSD17B10PTGS2
SCHEMBL28228188 0.74 KDM4E (0.49) KDM4EALDH1A1HPGDHSD17B10NPSR1
SCHEMBL29612310 0.74 PADI4 (0.73) KDM4EALDH1A1HPGDHSD17B10NPSR1
SCHEMBL19952906 0.74 PADI4 (0.73) KDM4EALDH1A1HPGDHSD17B10NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230227409-A1 QUINOLINONE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS IDEAYA BIOSCIENCES, INC. 2023-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230227409-A1 QUINOLINONE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS MAT2B, MAT2A, MAT1A KDM4E 1392/4885ALDH1A1 607/4885HPGD 1472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.